|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,562.50 INR | +1.13% |
|
+2.53% | +1.02% |
| 06-02 | Alkem Laboratories Limited Launches Semaglutide in Single-Shot Pre-Filled Syringes At Price Starting Inr 350 | CI |
| 06-02 | Alkem Laboratories Shows Strong Moves But Weak Follow-Through |  |
| Market Cap | 665B 6.99B 6.11B 5.61B 5.23B 9.92B 10.07B 67.37B 26.19B 327B 26.22B 25.66B 1,127B | P/E 2026 |
27.5x | P/E 2027 * | 28.4x |
|---|---|---|---|---|---|
| Enterprise Value | 637B 6.69B 5.85B 5.37B 5.01B 9.5B 9.65B 64.52B 25.08B 313B 25.11B 24.57B 1,079B | EV / Sales 2026 |
4.3x | EV / Sales 2027 * | 3.83x |
| Free-Float |
37.09% | Yield 2026 |
1% | Yield 2027 * | 0.93% |
Last Transcript: Alkem Laboratories Limited
| 1 day | +1.13% | ||
| 1 week | +2.53% | ||
| Current month | -0.13% | ||
| 1 month | +5.42% | ||
| 3 months | +5.79% | ||
| 6 months | -0.54% | ||
| Current year | +1.02% |
| 1 week | 5,394.5 |  | 5,639 |
| 1 month | 5,175.5 | | 5,639 |
| Current year | 5,075 | | 5,933.5 |
| 1 year | 4,716.2 | | 5,933.5 |
| 3 years | 3,447 | | 6,439.9 |
| 5 years | 2,828 | | 6,439.9 |
| 10 years | 1,341 | | 6,439.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Rajorshi Ganguli
PSD | President | - | - |
Akhilesh Sharma
PSD | President | - | - |
Nitin Agrawal
DFI | Director of Finance/CFO | - | 2024-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Sandeep Singh
BRD | Director/Board Member | 44 | 2013-08-08 |
| Director/Board Member | 63 | 2008-02-10 | |
Sarvesh Singh
BRD | Director/Board Member | 44 | 2019-11-10 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.13% | +2.53% | +13.84% | +59.17% | 6.99B | |
| +1.86% | +0.48% | +55.50% | +163.08% | 1,082B | |
| +3.57% | +3.29% | +68.60% | +61.03% | 633B | |
| +3.99% | +3.05% | +37.93% | +93.37% | 461B | |
| +3.86% | +1.64% | +31.35% | +24.29% | 338B | |
| -0.56% | +0.96% | +39.86% | +36.64% | 299B | |
| -0.08% | +1.30% | +30.37% | +44.02% | 291B | |
| -1.54% | +2.81% | -27.56% | -39.45% | 222B | |
| +3.55% | +4.41% | +25.45% | +66.28% | 202B | |
| +4.21% | +2.65% | +17.47% | +71.11% | 163B | |
| Average | +2.00% | +4.37% | +29.28% | +57.95% | 369.94B | |
| Weighted average by Cap. | +2.24% | +5.53% | +41.73% | +82.96% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 146B 1.54B 1.34B 1.23B 1.15B 2.18B 2.21B 14.81B 5.76B 71.88B 5.77B 5.64B 248B | 166B 1.74B 1.52B 1.4B 1.3B 2.47B 2.51B 16.77B 6.52B 81.38B 6.53B 6.39B 280B |
| Net income | 25.13B 264M 231M 212M 198M 375M 381M 2.55B 989M 12.35B 991M 969M 42.56B | 23.92B 251M 220M 202M 188M 357M 362M 2.42B 942M 11.76B 943M 923M 40.52B |
| Net Debt | -28.13B -295M -258M -237M -221M -420M -426M -2.85B -1.11B -13.83B -1.11B -1.09B -47.65B | -30.47B -320M -280M -257M -240M -455M -462M -3.09B -1.2B -14.98B -1.2B -1.18B -51.62B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-03 | ₹5,562.50 | +1.13% | 568,290 |
| 26-07-02 | ₹5,500.50 | -1.20% | 163,412 |
| 26-07-01 | ₹5,567.50 | -0.04% | 128,296 |
| 26-06-30 | ₹5,570.00 | +2.83% | 340,712 |
| 26-06-29 | ₹5,416.50 | -0.16% | 193,434 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALKEM Stock
Select your edition
All financial news and data tailored to specific country editions
